Research&Co
Lymph&Co funded research & fellowships awarded
In 2015, the first Lymph&Co-funded research was initiated at the AMC in Amsterdam by Prof. Dr. Marie-José Kersten, internist-hematologist and Prof. Dr. Steven Pals, pathologist: “Understanding lymphoma better: towards personalized therapy.”
Nine studies have now been funded.
The study on inhibition of KDM5 as a targeted therapy for KMT2D mutations in non-hodgkin lymphoma by Prof. Dr. Jude Fitzgibbon was stopped early due to the departure of several partners from the consortium.
The amount we funded has been repaid to us.
All studies funded by Lymph&Co at a glance:
Can inflammation generated in cancer cells by chromosomal instability be used to treat lymphoma? -Prof. dr. ir Floris Foijer
UMC Groningen
Contribution: € 698,877
Duration 2024 – 2027
Professor Floris Foijer’s research group at the UMC Groningen, with support from Lymph&Co, will conduct research on the effect of anti-inflammatories on the treatment of lymphoma.
Chemical degradation of CBP/p300 to treat lymph node cancer -Dr. Christopher Ott
Massachusetts General Hospital – USA
Contribution: € 1000,000.-
Duration: 2022 – 2026
Dr. Christopher Ott’s research group at Massachusetts General Hospital and Harvard Medical School is engaged in creating and testing drugs to treat lymphoma.
Investigation of inhibition of KDM5 as targeted therapy for KMT2D mutations in non-Hodgkin lymphoma.
-Prof. Dr. Jude Fitzgibbon
Queens Mary’s Barts Cancer Institute – London
Due to the departure of several partners from the consortium, it was no longer possible to conduct the research as proposed in the grant application.
Therefore, Lymph&Co has decided to withdraw its support.
Treatment of CLL/SLL with enhanced immunotherapy (Chimeric Antigen Receptor T-cells (CAR-T)). -Prof. Dr. Arnon Kater
Amsterdam UMC
Contribution: € 824,000
Duration: 2021 – 2025
Small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL) are two forms of the same disease.
In SLL, the malignant B cells are mainly in lymph nodes and in CLL in both lymph nodes and blood.
Evasion of the cytotoxic immune response during the development of T-cell lymphoma.
-Dr. Aileen Rowan
Imperial College London
Contribution: € 708,297
Duration: 2021 – 2025
Dr. Aileen Rowan and her team are investigating whether a therapy can be found that can prevent the development of Adult T-cell Lymphoma, ATL.
V-D-J recombined B-cell receptors as leads for immunotherapy against lymphoma.
-Dr. Marianne Boes
UMC Utrecht
Contribution: € 385,000
Duration: 2020 – 2024
In 2015, over 1800 people were diagnosed with aggressive non-hodgkin lymphoma in the Netherlands; the average survival rate is now only about 62%.
‘Homelessness’ as therapy
– Dr. Marcel Spaargaren
Amsterdam UMC
Contribution: € 720,000,-
Duration: 2018 – 2022
Lymphoma is a malignant derangement of immune cells, mostly B lymphocytes.
For their growth and survival, lymphoma cells are highly dependent on, or even addicted to, signals from their microenvironment.
Understanding the uninhibited growth of lymphoma cells
-Dr. Joost Kluiver and Prof. Dr. Anke van den Berg
UMC Groningen
Contribution: € 772,000
Duration: 2017 – 2021
Lymphoma is a cancer of the white blood cells and can be divided into several variants with great differences in degree of aggressiveness and cure rate.
Understanding lymphoma better.
Towards personalized therapy – Prof. Dr. Marie José Kersten, internisthematologist and Prof. Dr. Steven Pals, pathologist
Amsterdam UMC
Contribution: € 500,000
Duration: 2015 – 2019
About one in 50 people will be diagnosed with lymphoma during his or her lifetime.
More than 4,000 new patients are diagnosed each year in the Netherlands alone, and this number is increasing.
Fellowships awarded
What role does the immune system play in treatment with CAR-T cells for aggressive lymphoma?
– Troy Noordenbos
Stanford University, California
Duration: 2023 – 2025
How patients with aggressive lymphomas respond to treatment varies.
This is because of the tumor cells themselves as well as how the immune system works in them.
We try to understand these complicated responses by studying pieces of the tumor (biopsies).
Investigating the toxicity and efficacy of CAR T-cell therapy.
– Marijn Kramer
Stanford University, California
Duration: 2022 – 2024
The goal of the study is to reduce HLH/MAS after CAR T cell therapy. First, she examines how the HLH/MAS arises. Next, they investigate how CAR T cells can be made differently.
New therapeutic strategies for the treatment of mantle cell lymphoma with mutations in the ATM gene. – Mathilde de jong
Max Planck Institute for Biology of Ageing
Duration: 2021 – 2023
Mantle cell lymphoma is a B cell lymphoma caused by mutations in the genes involved in regulating cell growth, response to DNA damage and survival pathways. Mathilde will research mantle cell lymphoma with mutations in the ATM gene.
